x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Oncology On The Go

Oncology On The Go is a weekly podcast that talks to authors and experts to thoroughly examine featured articles in the journal ONCOLOGY and review other challenging treatment scenarios in the cancer field from a multidisciplinary perspective. Our discussions also offer timely insight into topics ranging from recent FDA approvals to relevant research presented at major oncology conferences. As the home of the journal ONCOLOGY, CancerNetwork offers different perspectives on oncology/hematology

science medicine

All Episodes

24:30

S1 Ep32: ScaleReady’s Work to Make Cell and Gene...

Oncology On The Go ·

2021/09/27

This week, CancerNetwork spoke with Josh Ludwig, Global Director of Commercial Operations at ScaleReady, about how this joint venture between industry leaders launched in January, is uniquely positioned to make cell and gene therapy practical and viable. Ludwig elaborated on how ScaleReady can support the entire industry, now and into the future, with a manufacturing platform that delivers a high throughput and efficient use of space. He also discussed G-Rex closed-system bioreactors, important

en-us

18:14

S1 Ep31: Inside the Advancing Inclusive Research Site...

Oncology On The Go ·

2021/09/13

CancerNetwork spoke with Quita Highsmith, Vice President and Chief Diversity Officer for Genentech, and Monica Baskin, PhD, a professor of preventive medicine and associate director for Community Outreach and Engagement for the O’Neal Comprehensive Cancer Center in Birmingham, Alabama. The conversation focused on the Advancing Inclusive Research Site Alliance, which is a coalition of clinical research sites partnering with Genentech to advance representation of diverse patient populations in

en-us

18:13

S2 Ep10: Two Experts Review Important R/R DLBCL...

Oncology On The Go ·

2021/08/30

For the final installment of a 3-part relapsed/refractory DLBCL series, CancerNetwork heard from Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, and Kami Maddocks, MD, an associate professor of clinical internal medicine in the Division of Hematology at The Ohio State University Wexner Medical Center. These lymphoma experts spoke about their thoughts on data from the L-MIND trial, when to implement CAR-T cell therapies for patients, the

en-us

20:09

S2 Ep9: OncView™ Podcast: Updates in Therapies of...

Oncology On The Go ·

2021/08/25

As part of its OncView™ video series, CancerNetwork® spoke with Javier Munoz, MD, MS, FACP, from the Mayo Clinic in Phoenix, Arizona, about updates in therapies of relapsed/refractory follicular lymphoma. In the video series, Javier Munoz, MD, MS, FACP, discussed the following: · Current Treatment Options for Relapsed/Refractory Follicular Lymphoma · Factors in Choosing R/R FL Treatments · Treatment Options for Third-Line R/R FL · Use of Tazemetostat for R/R FL ·

en-us

23:22

S2 Ep8: OncView™ Podcast: NCCN Guideline Updates in...

Oncology On The Go ·

2021/08/20

As part of its OncView™ video series, CancerNetwork® spoke with Lee Schwartzberg, MD, FACP, of the West Cancer Center and Research Institute in Germantown, Tennessee, about updates to the National Comprehensive Cancer Network (NCCN) guidelines regarding hormone receptor (HR)–positive breast cancer. In the video series, Lee Schwartzberg, MD, FACP, discussed the following: · Extended Adjuvant Therapy for HR+ Breast Cancer · Molecular Biomarkers for HR+ Breast Cancer · Role of

en-us

30:00

S1 Ep30: Routine Breast Cancer Screening in...

Oncology On The Go ·

2021/08/16

This week's podcast focuses on a review article published in the June issue of the journal ONCOLOGY titled, “Routine Breast Cancer Screening in Average-Risk Women Younger Than 50 Years: Current Paradigms Based on National Guidelines.” CancerNetwork spoke with Anath Ravi, PhD, co-founder and chief science and clinical officer of MOLLI Surgical, and Randy Miles, MD, MPH, an assistant professor in the Department of Radiology and clinical service chief in the Division of Breast Imaging at Massachusetts

en-us

15:05

S1 Ep29: Examining Evidence Underlying the NCCN...

Oncology On The Go ·

2021/08/02

This week, CancerNetwork review an article published in the July issue of the journal ONCOLOGY titled, “Level of Scientific Evidence Underlying the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies.” CancerNetwork spoke with Thejaswi Poonacha, MD, MBA, a staff physician and hospitalist in the department of internal medicine at the University of Minnesota Medical Center, regarding the research from him and his colleagues. The conversation focused on the

en-us

14:25

S2 Ep7: Kami Maddocks, MD, on Rituximab Rechallenging...

Oncology On The Go ·

2021/07/30

CancerNetwork spoke with Kami Maddocks MD, an associate professor of clinical internal medicine in the Division of Hematology at The Ohio State University, about CD-19 directed agents, avoiding rechallenging with rituximab, and second-line outcomes for transplant-ineligible patients with diffuse large B-cell lymphoma (DLBCL). Visit cancernetwork.com to check out the first episode of this 3-part series here. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple

en-us

15:45

S1 Ep28: Considering Second-Line Treatment Amidst...

Oncology On The Go ·

2021/07/19

This week, CancerNetwork® examined an article from the June issue of the journal ONCOLOGY® titled “Second-Line Therapies in the Changing Landscape of First-Line Therapies for Metastatic Clear Cell Renal Cell Cancer” by speaking with one of the authors, Robert A. Figlin, MD. Figlin, who is a professor of medicine and biomedical sciences, Steven Spielberg Family Chair in Hematology-Oncology, and deputy director of Cedars-Sinai Cancer at the Cedars-Sinai Medical Center in Los Angeles, California,

en-us

35:24

S2 Ep6: OncView™ Podcast: Updates in Managing...

Oncology On The Go ·

2021/07/16

As part of its OncView™ video series, CancerNetwork® spoke with Benjamin Levy, MD, of the John Hopkins Sidney Kimmel Comprehensive Cancer Center, to discuss frontline management of extensive-stage small cell lung cancer (SCLC) and the recent updates in the field. In the video series, Levy discussed the following: · Small Cell Lung Cancer: Risk and Prognosis · Small Cell Lung Cancer: Standard of Care · Extensive-Stage Small Cell Lung Cancer: Gaps in Treatment ·

en-us

27:59

S1 Ep27: BPCIA, 4-Letter Suffix Rule, & the...

Oncology On The Go ·

2021/07/05

In this episode, CancerNetwork spoke with 2 experts on the topic of biosimilars, Howard Hochster, MD, FACP, Associate Director for Clinical Research at the Rutgers Cancer Institute of New Jersey and Distinguished Professor of Medicine at the Rutgers School of Medicine, and Michael Kane, RPh, BCOP, Executive Director of Oncology Pharmacy Services for RWJBarnabas Health and Director of Pharmacy Services and the Research Pharmacy at the Rutgers Cancer Institute of New Jersey. The episode dives into

en-us

26:34

S2 Ep5: Emerging and Existing Treatment Regimens for...

Oncology On The Go ·

2021/06/30

In this episode, CancerNetwork spoke with Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, about recently approved and emerging treatment regimens for transplant-ineligible diffuse large B-cell lymphoma (DLBCL). Salles discussed some of the available treatment options including tafasitamab, CAR T-cell therapies, selinexor, and antibody drug conjugates (ADCs). He also looked ahead at some of the upcoming research on the horizon, including

en-us

27:42

S2 Ep4: OncView Podcast: Front-Line Management of...

Oncology On The Go ·

2021/06/28

As part of the OncView video series, CancerNetwork spoke with Mark Socinski, MD, of the AdventHealth Cancer Institute in Orlando, Florida about updates in the management of extensive-stage small cell lung cancer (ES-SCLC). Socinski touched on a number of important aspects of treating this disease, including the existing standards of care, treatment challenges, immunotherapy, IMpower 133 trial, and more. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast wherever you get your

en-us

29:42

S1 Ep26: Molecular Profiling Practices in Pancreatic...

Oncology On The Go ·

2021/06/21

This week, "Oncology Peer Review On-The-Go" discussed an article from the May issue of the journal ONCOLOGY titled “Molecular Profiling Practices in Pancreatic Adenocarcinoma: Academic vs Community Physicians.” CancerNetwork spoke with Christine Chung, DO, from the HCA Swedish Medical Center in Englewood, Colorado, about the molecular profiling patterns she and her colleagues observed in this retrospective review. The authors found that both academic and community physicians ordered profiling about

en-us

29:07

S2 Ep3: OncView™ Podcast: Management of...

Oncology On The Go ·

2021/06/17

As part of its OncView™ video series, CancerNetwork® spoke with Sameh Gaballa, MD, of the Moffit Cancer Center, about current and future treatment options, and considerations for patients with relapsed/refractory follicular lymphoma. In the video series, Gaballa discussed the following: · Treatment Options in Relapsed/Refractory Follicular Lymphoma · Considerations for Treatment Selection in R/R FL · Third-Line Therapy in Follicular Lymphoma · Tazemetostat for

en-us

26:42

S1 Ep25: Primary Focal Therapy for Localized Prostate...

Oncology On The Go ·

2021/06/07

The May issue of the journal ONCOLOGY featured a review article titled “Primary Focal Therapy for Localized Prostate Cancer: A Review of the Literature.” Sudhir Isharwal, MD, an assistant professor in the Department of Urology at Oregon Health & Science University in Portland, Oregon, discussed the emergence of focal therapies in the last few years for the treatment of patients with localized prostate cancer. This literature review investigated some of the advantages and drawbacks of various

en-us

14:02

S1 Ep24: Treatment Considerations for...

Oncology On The Go ·

2021/05/24

The feature article for this episode comes from the April issue of the Journal ONCOLOGY titled “Treatment Considerations for Transplant-Ineligible Multiple Myeloma.” Sarah Holstein, MD, an associate professor of internal medicine in the Division of Oncology & Hematology at University of Nebraska Medical Center in Omaha, Nebraska, spoke about the need for further research into treatment options for the older and more frail patient population of multiple myeloma. Holstein also explained the

en-us

16:53

S2 Ep2: OncView Podcast: Optimizing Treatment With...

Oncology On The Go ·

2021/05/19

As part of its OncView video series, CancerNetwork spoke with Reshma L. Mahtani, DO, Sylvester Comprehensive Cancer Center, about the current role of genomic testing in HR-positive breast cancer and guidance on the use of genomic assays to individualize therapy in the extended adjuvant setting. In the video series, Gadi discussed the following: · Extended Adjuvant Therapy for HR+ Breast Cancer · NCCN Updates to Genomic Testing in HR+ Breast Cancer · Genomic Testing for HR+ Breast

en-us

26:18

S2 Ep1: OncView Podcast: Genomic Testing in HR+...

Oncology On The Go ·

2021/05/18

As part of its OncView video series, CancerNetwork spoke with Vijayakrishna (VK) Gadi, MD, PhD, University of Illinois College of Medicine, about the current role of genomic testing in HR-positive breast cancer and guidance on the use of genomic assays to individualize therapy in the extended adjuvant setting. In the video series, Gadi discussed the following: · Adjuvant Vs Extended Adjuvant Therapy in HR+ Breast Cancer · Predictive and Prognostic Factors in HR+ Breast Cancer ·

en-us

36:20

S1 Ep23: A Critical Interval to Delay Progression of...

Oncology On The Go ·

2021/05/10

This episode features an article published in the April issue of the Journal ONCOLOGY titled “Focus on Transitional Disease: A Critical Interval to Delay Progression of Prostate Cancer.” The lead author of the research, E. David Crawford, MD, a urologic oncologist, and professor of urology at the University of California San Diego, explained their research into prostate cancer disease states. Among other things, Crawford and the research team talked about next-generation imaging, biomarkers, and

en-us

222 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter